# NK-cell & CAR-NK therapy CAR-NK and NK-cell therapy — allogeneic, off-the-shelf effector cells with low toxicity (minimal CRS, no GVHD) against solid and haematological cancers; iPSC-NK is the scalable platform. Source: https://en.bioecon.ru/technology/nk-cell-car-nk-therapy/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: ATMP Regulation (EC No 1394/2007) | OECD: Bio-Pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)] NK-cell therapy (Natural Killer) and CAR-NK use innate effector cells to kill tumors. Unlike autologous CAR-T, NK cells are allogeneic, "off-the-shelf": donor- or iPSC-derived, with no GVHD risk and minimal CRS. CAR-NK carries a chimeric antigen receptor (e.g. anti-CD19 or NCG2D) for tumor-antigen recognition. The iPSC-NK platform (Fate Therapeutics) yields scalable, standardised batches from a single cell line. Early-clinical responses reach 60–80% in haematological cancers, with a better toxicity profile than CAR-T. Key platforms of NK therapy: 1. **CAR-NK (CAR-NK):** NK with a CAR (anti-CD19, NKG2D) — directed cytotoxicity. 2. **iPSC-NK (iPSC-derived NK):** standardised NK from induced pluripotent stem cells — scale. 3. **Cord-blood NK (Cord-blood NK):** donor NK from umbilical-cord blood (Takeda/MD Anderson). 4. **NK engagers (NK-cell Engagers):** bispecifics linking NK to tumor (Affimed). ### Sectoral value chain ``` [donor/iPSC line] ──> [NK manufacture + expansion] ──> [CAR transduction (optional)] │ (cryopreservation / QC) │ ▼ [patient] <─── [off-the-shelf infusion] <─── [allogeneic dose release] ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Cell Source** | iPSC line or donor cord blood | **In:** iPSC/blood. **Out:** cell source. | | **NK Differentiation/Expansion** | NK differentiation/expansion (14–21 days) | **In:** source, cytokines. **Out:** NK pool. | | **CAR Engineering** | lentiviral CAR transduction (optional) | **In:** NK pool, vector. **Out:** CAR-NK. | | **Fill & Cryostore** | fill, cryopreserve off-the-shelf doses | **In:** CAR-NK. **Out:** cryobanked doses. | | **Infusion (Off-the-shelf)** | thaw and infuse without patient lymphodepletion | **In:** dose, patient. **Out:** infused patient. | | **Follow-up** | response, CRS, NK persistence monitoring | **In:** patient. **Out:** therapy outcome. | Cross-cutting technologies of the sector: - **iPSC platform (iPSC Platform):** standardised, scalable NK batches from one line. - **Off-the-shelf:** ready doses — no autologous-manufacturing delay (vs CAR-T). - **NK-cell engagers:** bispecifics (Affimed) — link NK to tumor without a CAR. --- ## US The US leads CAR-NK design on an iPSC base (Fate, Nkarta), with NCI support. ### Fate Therapeutics, Nkarta, NCI funding - **Fate Therapeutics:** iPSC-NK platform — standard batches from a single line. - **Nkarta:** NKX101 (NKG2D CAR-NK) — phase I in acute myeloid leukaemia. - **NCI:** grants for fundamental and translational NK research. --- ## CN China is rapidly adopting CAR-NK in solid and haematological cancer trials. ### Clinical scale-up, NMPA pathway, domestic platforms - **Clinical experience:** CAR-NK in hepatocellular carcinoma and lymphomas. - **Domestic platforms:** local CAR-NK developers under NMPA. - **NMPA:** accelerated pathways for strategic cell-therapy candidates. --- ## EU The EU is strong in allogeneic platforms and NK-cell engagers. ### Affimed engagers, EMA ATMP, academic NK programs - **Affimed (Germany):** bispecific NK-cell engagers (ICE®) — link NK to tumor. - **EMA ATMP:** allogeneic NK classified as ATMP; strict donor oversight. - **Academic programs:** university NK protocols (Germany, Netherlands). --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Nkarta** | 🇺🇸 USA | *NKX101* (NKG2D CAR-NK) | phase I AML | Scaling | | **Fate Therapeutics** | 🇺🇸 USA | iPSC-NK platform | standard batches from iPSC | Scaling | | **Takeda** | 🇯🇵 Japan | CD19-CAR-NK (with MD Anderson) | cord-blood, phase II lymphoma | Scaling | | **Artiva Biotherapeutics** | 🇺🇸 USA | allogeneic NK (AB-101) | off-the-shelf cord-blood doses | Scaling | | **Affimed** | 🇩🇪 Germany | NK-cell engagers (ICE®) | CAR-free bispecifics | Scaling | | **MD Anderson** | 🇺🇸 USA | academic CAR-NK | CD19-CAR-NK with Takeda | Research | --- ## Tech stack and innovations The stack rests on iPSC-NK, off-the-shelf logistics and engagers. 1. **iPSC-NK (iPSC-derived NK):** - standardised NK from a single iPSC line — scalable batches. 2. **Off-the-shelf:** - cryobanked ready doses — infusion without autologous-manufacturing delay. 3. **NK-cell engagers:** - bispecific molecules (Affimed ICE®) link NK to tumor without engineering the cell. --- ## Value chains and production pipelines ### Allogeneic CAR-NK manufacturing pipeline (ATMP / cGMP) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Source (iPSC/cord) │ ───> │ 2. NK expansion (14–21 d) │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Fill & cryopreservation│ <─── │ 3. CAR transduction (opt.)│ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Release ready dose │ ───> │ 6. Infusion (off-the-shelf)│ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Cell source An iPSC line or donor umbilical-cord blood as the starting material. #### Stage 2: NK expansion NK differentiation/expansion with cytokines (IL-2, IL-15) over 14–21 days. #### Stage 3: CAR transduction (optional) Lentiviral CAR transduction (anti-CD19/NKG2D) for CAR-NK. #### Stage 4: Fill & cryopreservation Filling into doses, cryopreservation of the ready allogeneic product. #### Stage 5: Dose release Quality control (sterility, viability, potency); release of the ready dose. #### Stage 6: Infusion Thaw and infusion to the patient (off-the-shelf, often without deep lymphodepletion); response and NK-persistence monitoring.